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Summary In the present work, eight conformationally constrained analogues of the p specific opioid peptide 
dermorphin were synthesized by replacing D-Ala2 with stereoisomers of p-amino-cycloalkane or cycloalkene carboxylic 
acids. The resulting peptides were tested for their potency to p and 8 opioid binding sites of rat brain membranes 
labelled with pHJTyr'-D-Ala^MePhe^Gly-ol, [3H]DAMGO and [3H]lles-6deltorphin, respectively. All of the new derivatives 
displayed highly attenuated binding to both receptor types, albeit the decrease in their potency seemed to be less in the 
case of S binding. Trans position of the p-amino groups resulted in higher binding affinities than that of the 
corresponding cis isomers, the latter being more flexible than the former. It is concluded that conformational constraints 
caused either by a rigid ring structure or cis isomers instead of D-Ala2 in dermorphin-derived peptides are unfavourable 
for binding activity to either opioid receptors. We propose that interaction of the larger heptapeptide derivatives of 
dermorphins with the p receptor is distinct from that of the tetrapeptide morphiceptin. 
INTRODUCTION 
Opioid peptides are a family of structurally related neuro-
modulators which play a crucial role in controlling the 
nociceptive pathways via p, S and K opioid receptors. The 
small peptides are usually highly flexible molecules and 
they may adopt different conformations required for 
recognition by different receptor types. Indeed, previous 
binding experiments performed with rat brain mem-
branes and recent data with recombinant receptors 
suggest that no opioid peptide family can be exclusively 
associated with a specific opioid receptor type.' 
However, mapping the specific structural requirements 
of individual receptor types and elucidation of their 
unique physiological role would require highly site-
specific ligands. During recent years, enormous synthetic 
efforts have been made to achieve this goal. More than 
1000 analogues of the enkephalins, p-casomorphins. 
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deltorphins, dynorphins and p-endorphin have been syn-
thesized to date2 (and references cited therein). The pio-
neering work of Hruby et al and Schiller et al revealed 
that conformational constraints are absolute require-
ments for achieving p-selective peptide binding.3-4 
Local constraints5-8 can be introduced in the peptide 
backbone by employing N°-methylated amino acids 
(which will restrict the O torsion angle, O = - 120° ± 20°), 
proline (<D = - 70° ± 20°,) or cyclic P-amino acids. 
Formation of mono- or polycyclic structures like disul-
phide bridges, cyclising the side-chain to the backbone 
or cyclising the C-terminus to the N-terminus also 
reduce the conformational freedom of peptides. 
In contrast to all mammalian opioid peptides, dermor-
phin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NHj) originally 
isolated from amphibian skin, contains a D-amino acid in 
the second position of the sequence and a C-terminal car-
boxamide group and is therefore relatively stable against 
enzymatic degradation.9 The natural heptapeptide shows 
remarkably high p selectivity which is comparable to that 
of p-casomorphins isolated from bovine milk.10 By substi-
tuting Pro for p-aminocyclopentane carboxylic acid 
(PAc5c) in the N-terminal tetrapeptide of the latter, Tyr-
Pro-Phe-Pro-NH2 (morphiceptin), it was concluded by 
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Mierke et al that Pro2 is crucial as pan of a constrained 
topology to maintain the proper orientation of the side 
chains of Tyr and Phe, but the cis/trans isomerization 
between Tyr-Pro is not important for biological activity." 
In the present study, eight conformationally con-
strained analogues of dermorphins were synthesized by 
replacing D-Ala2 with (Tamino-cyclic car boxy lie acids. 
The resulting peptides were tested for their binding activ-
ity to p and 8 opioid receptors in rat brain membranes. It 
was concluded that the presence of a rigid cyclic ring 
instead of D-Ala2 in dermorphin-derived peptides is con-
formationally unfavourable for binding activity to either 
opioid receptor. 
M A T E R I A L S A N D M E T H O D S 
Chemicals 
Dichloromethane (DCM), dimethylformamide (DMF), di-
isopropyl-ethylamine (DIEA), methanol (MeOH), trifluo-
roacetic acid (TFA) and HPLC grade acetonitrile (AcN) 
were purchased from E. Merck (Darmstadt, Germany) 
and were used without further purification. Fluka (Buchs, 
Switzerland) supplied puriss grade dicyclohexylcarbodi-
imide (DCQ. Protected amino acid derivatives and 
DAMGO (Tyr'-D-Ala2-MePhe4-Gly-ol) were from Bachem 
Inc. (Torrance, CA, USA). 1-Hydroxy-benzotriazole 
(HOBt), p-cresol, dimethylsulphide were purchased from 
Aldrich (Steinheim, Germany). Hydrogen fluoride (HF) 
was obtained from UCAR (Olen, Belgium). 
[3H]naloxone (71.3 Ci/mmol) and [3H]DAMGO (55 Ci/ 
mmol) were obtained from New England Nuclear 
(Boston, MA, USA). [3H]Iles-6-deltorphin (49.5 Ci/mmol) 
was synthesized by us.12 Naloxone hydrochloride was 
kindly donated by S. Hosztafi (Alkaloida Ltd, 
Tiszavasvari, Hungary). Other chemicals were from 
Sigma (St Louis, MO, USA). 
S Y N T H E S I S O F T H E B U I L D I N G B L O C K S 
The alicyclic p-amino acids, namely cis- and trans-2-
aminocyclohexane-l-carboxylic acid, cis- and trans-2-
amino-4-cyclohexene-l-carboxylic acid, diexo- and 
diendo-3-arninobicyclo[2.2.1 ]heptane-2-carboxylic acid 
and diexo- and diendo-3-aminobicyclo[2.2.1]hept-5-ene-
2-carboxylic acid were prepared as described in earlier 
reports.13- '6 Two methods were used. Compounds I, IV, 
VII and VIII were prepared from the corresponding dicar-
boxylic anhydride by ammonolysis and Hofman degra-
dation followed by ion exchange purification. In the case 
of III, IV and VIII the Hofman degradation was per-
formed using sodium hypochlorite.1415 Amino acids V 
and VI were prepared by cycloaddition of norbornane or 
acooH ^ ^ c o o H 
NH2 / - "^ - -X NH2 / ^ C - J ^ NH2 
( I ) (111) ( V ) ( V I I ) 
COOH COOH ^ ^ ^ 
^ ^ NH, '< NH2 XNHj \NH2 
( I I ) ( I V ) ( V I ) ( V I I I ) 
Rg. 1 Structure of cis (upper row) and trans (lower row) p-amino-
cyclic-cart>oxylic acids introduced into the second position of 
dermorphin 
norbomadiene and chlorosulphonyl isocyanate, result-
ing in azetidinones which were transformed to amino 
acids by aqueous hydrogen chloride treatment.1316 The 
structure of these amino acid derivatives, which were 
built into the second position of dermorphin (DMF) to 
gain the new peptides, is shown in Figure 1. 
P E P T I D E S Y N T H E S I S 
The peptides were synthesized by solid phase techniques 
utilizing 'Boc chemistry.17 Side-chain protecting groups 
were as follows: Tyr(BrZ) and Ser(Bzl). The peptide chains 
were elongated on MB HA (p-methylbenz-hydrylamine) 
resin (0.6-0.8 mmol/g) and the syntheses were carried 
out manually. Couplings were performed with DCC. 
Incorporation of the amino acids was monitored by the 
ninhydrin test.18 In case of incomplete couplings this step 
was repeated, but the DCM was substituted by DMF. The 
completed peptide resins were treated with liquid 
HF/dimethyl sulphide/p-cresol/p-thiocresol (86 : 6 : 4 : 2, 
vol/vol) at 0°C for 1 h. HF was removed and the resultant 
free peptides were solubilized in 10% aqueous acetic 
acid, filtered and lyophihzed. 
P E P T I D E P U R I F I C A T I O N 
The crude peptides were purified by reverse-phase HPLC 
with a Lichrosorb RP-18 10 p column (16 x 250 mm). The 
HPLC apparatus was made by Knauer (Berlin, Germany). 
The solvent system following was used: 0.1% TFA in 
water, 0.1% TFA, 80% AcN in water, gradient: 0% -> 50% 
B in 1.5 h, flow 3 ml/min. The appropriate fractions were 
pooled and lyophihzed. The purity was checked by RP-
HPLC (Nucleosil 5 C 18 column, the upper solvent sys-
tem, gradient: 25% 45% B in 20 min, flow 1 ml/min 
detection at 220 nm and proved to be substantially pure 
(> 97%). 
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Table 1 Structural and analytical characterization of the peptides synthesized in this work based on the structure 
Tyr'-X2-Phe3-Gly4-Tyrs-Pro6-Ser7-NHj" 
Amino acid in position 2 Peptide Calculated M Found M R, 
c/s-2-amino-cyclohexane DMF58 857.1 857.8 9.51 
carboxylic acid (I) 
frans-2-amino-cyclohexane DMF61 857.1 857.8; 11.31 
carboxylic acid (II) 856.4t 
crs-2-amino-cyclohexene DMF59 855.1 855.9 11.17 
carboxylic acid (III) 
trans-2-amino-cyclohexene DMF60 855.1 855.8 10.95 
carboxylic acid (IV) 
crs-2-amino-norbomane DMF68 869.1 869.8 11.19 
carboxylic acid (V) 
frans-2-amino-norbomane DMF70 869.1 869.8 9.63 
carboxylic acid (VI) 
crs-2-amino-norbomane DMF63 867.1 867.8 9.38 
carboxylic acid (VII) 
frans-2-amino-norbomane DMF62 867.1 867.9 9.68 
carboxylic acid (VIII) 
'Dermorphin if X: D-Ala. 
rpab MS measurement, the others are from quadrupole electrospray spectra. 
MASS SPECTROMETRY 
The FAB-MS experiments were performed with a VG 
ZAB-2SEQ type hybrid tandem mass spectrometer, 
equipped with an LSIMS source (Cs* ion gun used at 
30 keV). The electrospray MS experiments were made on 
a FINNIGAN TSQ 7000 tandem quadrupole spectrometer 
equipped with an electrospray ion source. The results of 
the MS measurements in all cases were in good agree-
ment with the calculated values as shown in Table 1. 
MEMBRANE PREPARATION 
A crude membrane fraction of Wistar rat brains was pre-
pared as previously described.'9 Briefly, the animals were 
decapitated, their brains without cerebella rapidly 
removed and homogenized in 30 volumes of ice-cold 
50 mM Tris-HCl (pH 7.4) buffer by a teflon-glass homoge-
nizer. After centrifugation at 20 000 x g for 25 min the 
resulting pellets were resuspended in 30 volumes of 
buffer and incubated for 30 min at 37°C to remove 
endogenous opioids. Centrifugation was then repeated as 
described above. The final pellet was suspended in 5 vol-
umes of 50 mM Tris-HCl (pH 74) buffer containing 
0.32 M sucrose and stored at - 70°C. Membranes were 
thawed before use, diluted with buffer and centrifuged at 
20 000 x g to remove sucrose. The resulting pellets were 
suspended in 60 volumes of buffer to give a protein con-
centration of about 0.3-0.5 mg/ml and immediately used 
in binding experiments. Protein contents of membrane 
preparations were determined by the method of Bradford 
using bovine serum albumin as standard.20 
BINDING ASSAY 
800 pi membrane suspension (=0.2-0.4 mg protein) was 
incubated with the appropriate [3H]-labelled compounds 
in 1 nM concentration ([3H]naloxone for 60 min at 0°C, 
[3H]DAMGO for 60 min at 25°C, [3H]fle5-4deltorphin II for 
45 min at 35°Q in the absence (total binding) or pres-
ence of lO-'o-lO-4 M of the peptides to be investigated in 
a final volume of 1 ml in plastic vials. The non-specific 
binding was determined with 10~s M naloxone and sub-
tracted from the total value to yield specific binding. The 
reactions were stopped by filtration through Whatman 
GF/B ([3H]naloxone) or GF/C filters ([3H]DAMGO and 
[3H]Iles<sdeltorphin II) utilizing a Brandel M24-R Cell 
Harvester (Gaithersburg, MD, USA). Filters were washed 
twice with 10 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer 
and dried. Radioactivity was determined in a toluene-
based scintillation cocktail in a Beckman LS 5000TD 
counter. All experiments were carried out as duplicate 
assays and repeated at least three times. The inhibitory 
constant, K, of the peptides was calculated from heterolo-
gous displacement curves with the LIGAND computer 
program.21 
RESULTS AND DISCUSSION 
Figure 1 shows the structures of alicyclic-p-amino-car-
boxylic acids (p-Acc) which were used to replace D-Ala2 
in dermorphin. While the cis-p-Acc residues (I, III) intro-
duced significant constraints into the peptide, the trans 
residues of the same substituents (II, IV) were more con-
formationaUy flexible. 
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logfUGAND], M 
Fig. 2 Competition of dermorphin analogues for rat brain opioid 
receptors. Crude membrane fraction was incubated with 
[3H]naloxone (1 nM), and the following unlabelled ligands DMF (x), 
DMF-58 (o). DMF-59 ( • ) . DMF-60 (A), DMF-61 (•), DMF-62 ( • ) . 
DMF-63 ( • ) , DMF-68 (V). DMF-70 (T) in 50 mM Tris-HCI (pH 7.4). 
(A) Symbols represent the mean ± SEM, n > 2; (B) symbols 
represent data from a single experiment. 
lOfllLIGAND], M log(LIGAND), M 
Fig. 3 Displacement of (A) pH)DAMGO or (B) [3H]lle56 deltorphin 
II binding by various concentrations of DAMGO (+). DMF-60 (A). 
DMF-61 ( • ) , or DMF (x). Crude membrane fraction of rat brains 
was incubated with [3H]DAMGO (1 nM), or [3H]lle-5«-deltorphin 
(1 nM), unlabelled ligands and 50 mM Tris-HCI (pH 7.4) For other 
details see Materials and methods. Results are expressed as 
percentage of control binding, i.e. binding in the absence of 
displacers. Mean ± SEM, n = 3. When the error bars are smaller 
than the symbols, only the latter are depicted 
i. 
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The potency of the new ligands in competing for 
opioid receptors of rat brain membranes was first tested 
with the general opioid antagonist ligand, [3H]naloxone 
(Fig. 2). The parent peptide, dermorphin displayed the 
highest potency to opioid receptors, having an IC50 of 
about 50 nM in this assay. Substitution of its D-Ala2 by 
the rigid (f-Acc derivatives attenuated opioid binding; all 
of the new analogues possessed much lower affinity. 
DMF-68,-70,-63,-62 - with ligands that contain a bicyclic 
complex ring structure (cis- or trans-norbornane and 
norbornene, respectively) - were able to displace 
[3H]naloxone binding only at very high (100 pM) concen-
trations (Fig. 2B). 
The two relatively most potent new derivatives, DMF-
60 and DMF-61 ([trans-p-amino-cyclohexane carboxylic 
acid]2 and [trans-p-amino-cyclohexene carboxylic acid]2-
dermorphin) were further tested for their selectivity to p 
versus 6 opioid binding (Fig. 3, Table 2). The substituted 
ligands had weak binding (K in the micromolar range) to 
both opioid receptor types, although it seems that the 
loss of potency to [3H]Ile5-6-deltorphin sites was less than 
to [3H]DAMGO binding sites, thus conferring some '5-
preference' to these peptides (Table 2). The K values of 
DAMGO and dermorphin measured in these experiments 
are in good agreement with reported data2 (and refer-
ences cited therein). 
The naturally occurring dermorphins contain an N-ter-
minal tripeptide sequence Tyr-D-Xaa-Phe which is also 
present in deltorphins (delta-specific opioids). A study by 
Charpentier et al suggests that this common sequence 
motif is recognized by both p and 6 opioid receptors 
which is topologically distinct from the region (C-termi-
nal 'address' domain of the ligands) which ensures site-
specific interactions with the receptors.22 Tyr1, Pro2 and 
Phe3 are the important residues for the biological activity 
of one of the most selective agonists for the p-receptor, 
morphiceptin.8-"-23 By contrast, the endogenous mam-
malian opioid peptides (enkephalins, endorphins, dynor-
phins) are characterized by an identical N-terminal 
'message' tetrapeptide sequence Tyr-Gly-Gly-Phe.124 
Keeping in mind that besides these structurally diverse 
p-receptor preferring peptide ligands the prototypic p lig-
ands are the morphine-like opiate alkaloids, one might 
assume that there are multiple factors determining the 
binding selectivity of p-specific ligands. 
Much has been learned about the structural features of 
opioid receptors since the first successful cloning by 
Kieffer et al and Evans et al.25-26 The amino acid 
sequences of p- and 5-receptors are approximately 
60-70% similar with the primary variations occurring in 
the extracellular N-terminus and the intracellular C-ter-
minus domains and the external loops.27-29 The second 
and third transmembrane domains of opioid receptors 
contain conserved aspartate residues29 that are believed 
to form an ion pair with the positively charged nitrogen 
atom, which is a strict structural requirement common to 
all opioid ligands.30 In analogy with other G-protein cou-
pled receptors, it was suggested that an opioid 'binding 
pocket' is formed by the seven putative a helices, while 
their extracellular loops would discriminate various 
classes of opioid ligands and define their p, S and K selec-
tivity. However, recent studies utilizing chimeric recep-
tors and mutation studies combined with 3-D computer 
modelling have revealed the existence of multiple inter-
actions throughout the receptor molecule which display 
a unique binding pattern for each ligand, at least in the 
case of 5 receptor interaction.25-31-32 Moreover, the p and 8 
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Table 2 Binding affinities of opioid peptides to p and 5 opioid receptors in rat brain membranes 
[3H]DAMGO 
GO 
K (nM) 
PHJIle56 deltorphin II 
(5) 
K, (nM) K(6)/K,(p) 
DAMGO 3.3 ± 0.5 634±150* 192 
Dermorphin 1.7 ±0.5 158 ± 2 1 90 
DMF-60 2200 ± 460" 1620 ±290 0.73 
DMF-61 3390±1820 1170 ±270 0.34 
Results (mean ± SEM) of three independent measurements except" where n = 2. 
pharmacophore conformations adopted by one and the 
same compound, namely cyclic p-casomorphins, were 
also suggested to be distinct in a recent study by Brandt 
et al utilizing molecular modelling.33 
An interesting outcome of the present work is that 
introduction of rigid cyclic p-amino-carboxylic acids in 
the second positions of the peptide backbone leads to dif-
ferent effects for dermorphins (Figs 1&2, Table 2) than for 
casomorphins." Here the rigid cyclohexane, norbomane 
and their unsaturated analogues highly decrease the 
binding potency of the resulting compounds to p and 5 
opioid receptors. In contrast, Pro2 or other residues caus-
ing constrained topology are crucial for proper orienta-
tion of Tyr and Phe, thus for the biological activity of 
morphiceptin." We and others previously reported that 
introduction of D-Ala in position 2 of morphiceptin leads 
to an enhancement of the binding affinity to 5-sites, thus 
resulting in a reduced p-selectivity.10-23 Therefore we 
speculate that interaction of the larger heptapeptide 
derivatives of dermorphins with the p-receptor is distinct 
from that of the tetrapeptide morphiceptin. Indeed, the K 
value for the former was found to be 0.33 nM, while 
56 nM was reported for morphiceptin against the cloned 
p-opioid receptor by Raynor et al3 4 It cannot be excluded 
that these ligands would bind to different subtypes of p-
receptor, i.e. to the yet hypothetical p1 and p2 receptors35 
which might be distinct proteins, or different binding 
regions of the same protein. The latter was recently 
demonstrated to be the case with cloned kappa recep-
tors.36 Although such distinction still awaits in case of the 
p-receptor, the results of the present study describing the 
synthesis and binding characteristics of constrained der-
morphin derivatives contribute to the understanding of 
the structural and topographical requirements of peptide 
ligand binding. 
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Summary 
Met5-enkephal in-Arg6-Phe7 (Tyr-Gly-Gly-Phe-Met-Arg-Phe, MERF) is a naturally 
occurring heptapeptide that binds to opioid and non-opioid recognition sites in the central 
nervous system. Four synthetic analogs with single or double amino acid substitutions 
were prepared by solid phase peptide synthesis to achieve proteolytically more stable 
structures: Tyr-£M/<3-Gly-Phe-Met-Arg-Phe (I), Tyr-D-^/o-Gly-Phe-D-Me-Arg-Phe (II), 
Tyr-ZM/a-Gly-Phe-Z-Me-Arg-Phe (HI) and Tyr-Gly-Gly-Phe-Z-Me-Arg-Phe (IV). In this 
study receptor binding characteristics and G-protein activation of MERF and its 
derivatives were compared in crude membrane fractions of frog and rat brain. Synthetic 
MERF-derived peptides were potent competitors for [3H]MERF and [3H]naloxone binding 
sites with the exception of analog (II) which turned to be substantially less active. The 
presence of 100 mMNaCl or 100 pM 5'-guanylylimidodiphosphate, Gpp(NH)p, decreased 
the affinity of the peptides in [3H]naloxone binding assays, suggesting that these ligands 
might act as agonists at the opioid receptors. Some of the compounds were also used to 
stimulate guanosine-5'-0-(3-[y-[3jS]thio)triphosphate (["SlGTPyS) binding in rat and frog 
brain membranes at concentrations of io -¡o .vi. l n e tX/u\aiues o i unaiog w e r e t h e 
highest in both tissues. Analog (I) was as effective as MERF in rat brain membranes, but 
showed lower maximal stimulation in frog brain preparation. Again, analog (II) seemed to 
be the least efficacious peptide that stimulated [35S]GTPyS binding only by 59 %. 
Specificity of the peptides was further investigated by the inhibition of agonist-stimulated 
[35S]GTPyS binding in the presence of selective antagonists for the opioid receptor types. 
The p-selective antagonist cyprodime displayed the lowest potency in inhibiting the effects 
of the peptides, whereas norbinaltorphimine (x-selective antagonist) and naltrindole 
(8-selective antagonist) were quite potent in both tissues. We concluded that MERF and its 
derivatives are able to activate G-proteins mainly via K- and 8-opioid receptors. 
MetD-enkephalin-Arg6-Phe7 (Tyr-Gly-Gly-Phe-Met-Arg-Phe; MERF) was discovered 
chromaffin granules of bovine adrenal glands and also in beef striatal extracts (1). The peptide 
1 corresponding author: Dr. S. Benyhe, Inst. Biochem., Biol. Res. Ctr., Hung. Acad. Sci. H-6701 Szeged, 
P.O.B. 521, Hungary; fi: 36 62 432 232; Fax: 36 62 433 432, S : benyhe@nucleus.szbk.u-szeged.hu 
cleaved from proenkephalin-A and localized to the mammalian central nervous system (2). 
MERF has also been found in relatively high concentrations in the brain of lower vertebrates (3). 
The heptapeptide has been reported to be antinociceptive (4), and more recently its antitussive 
effect has been noted (5). 
Opioid receptor binding properties of MERF have been studied in various species using labelled 
oripavine- ([3H]etorphine) and benzomorphan-type ([3H]ethylketocyclazocine) ligands (6-8). 
These studies have led to the conclusion that MERF binds mainly to the so-called ^-binding 
sites, a benzomorphan-preferring subset of the K-opioid receptors (9, 10). In a more direct 
approach, MERF has been radiolabeled by catalytic dehalotritiation resulting in [3H]MERF with 
high specific radioactivity (11). Using this compound as a radioprobe we have demonstrated that 
[3H]MERF is able to interact selectively with the K2-receptors in frog (Rana esculenta) brain 
membranes (11). In rat brain membranes, K- and 8-opioid receptors and non-opioid binding sites 
have also been shown to be specifically labelled by [3H]MERF (12). The radiopeptide binds only 
to the non-opioid sites in guinea pig cerebellar membranes (13), where no K2- but KI-opioid 
receptors are present (9). 
Elongated enkephalins have been shown to be relatively sensitive to enzymatic degradation by 
peptidases (14), therefore selective inhibitors of enkephalin-degrading enzymes should be 
included in the assay mixtures. Another concern with MERF may be the oxidation of the 
methionine side chain by air. To overcome these difficulties, several synthetic peptides have been 
designed in which Gly2 is replaced by D-Ala2 to increase enzymatic stability, and/or Met5 is 
substituted with its isosteric amino acid norleucine (Nle), either as L-Nle5 or as D-Nle3. 
The aim of the present study is therefore to compare the receptor binding properties of the newly 
synthesized MERF-related peptides in frog and rat brain membrane preparations, the former 
representing a rich source of K2-opioid receptors (8). The compounds are also investigated in 
guanosine-5 '-0-(3-[y-[35S]thio)triphosphate ([35S]GTPyS) binding assays to uncover guanine 
nucleotide binding protein (G-protein) activation via opioid receptors by these peptides. Such 
experiments are again performed in both membrane preparations because a K-receptor mediated 
G-protein activation in frog brain has recently been reported (15). 
Materials and methods 
Chemicals: Radiolabeled guanosine-5'-0-(3-[v-[35S]thio)triphosphate ([35S]GTPyS) (37-42 
Tbq/mmol) was purchased from Isotope Institute Ltd., (Budapest, Hungary); [^Hjnaloxone (71.3 
Ci/mmol) was prepared as described (16); [3H]MERF ([3H]Tyr-GIy-GIy-Phe-Met-Arg-Phe, 40 
Ci/mmol) was also synthesized in the BRC Isotope Laboratory (Szeged, Hungary) as described 
previously (11). 
Synthetic MERF analogs 
( I ) : Tyr -D-Ala-Gly-Phe- Met- Arg-Phe, 
( I I ) : T y r - D - A l a - G l y - P h e - D - N l e - A r g - P h e , 
( I I I ) : Tyr - D - A J L a-Gly-Phe - L - N I e-Arg-Phe, 
(IV): Tyr- Gly- Gly-Phe - L - N l e-Arg-Phe 
were prepared by solid phase peptide synthesis and purified by reversed phase high-pressure 
liquid chromatography. Norbinaltorphimine (nor-BNI) and naltrindole were from ICN-Alkaloida 
(Tiszavasvari Hungary); trasylol (Gordox, aprotinin) and captopril was purchased from Gedeon 
Richter Pharmaceutical Company (Budapest, Hungary); bestatin, thiorphan, guanosine 5'-
diphosphate (GDP), unlabelled GTPyS, 5'-guanylylimidodiphosphate (GppNHp), 
ethylenediamine-tetraacetic acid (EDTA), ethylene glycol-bisfli-aminoethyl ether)-N,N,N',N'-
tetra-acetic acid (EGTA), phenylmethylsulfonyl fluoride (PMSF) and NaCl were products of 
Sigma Chemicals, St. Louis, MO, USA. 
Rat brain membrane preparations: A crude membrane fraction of Wistar rat brains was 
prepared for [3sS]GTPyS binding experiments according to Szucs et al. (17). Briefly, the animals 
were decapitated, their brains without cerebella rapidly removed and homogenized in 30 volumes 
of ice-cold 50 mM Tris-HCl (pH 7.4) buffer by a teflon-glass homogeniser. After centrifiigation 
at 20,000 x g for 25 min at 4°C the resulting pellets were suspended in 30 volumes of the same 
buffer and incubated for 30 min at 37°C to remove endogenous opioids. Centrifiigation was then 
repeated as described above. The final pellets were suspended in 5 volumes of 50 mM Tris-HCl 
(pH 7.4) buffer containing 0.32 M sucrose and stored at -70°C. Membranes were thawed before 
use, diluted with buffer and centrifiiged at 20,000 x g for 25 min at 4°C to remove sucrose. The 
resulting pellets were taken up in appropriate fresh buffer and immediately used in [35S]GTPyS 
binding experiments (see below). Membranes for [JH]MERF binding experiments were prepared 
as described (12). The final pellets were suspended in fresh buffer containing peptidase inhibitors 
(listed in 'radioligand binding studies') to give a protein concentration of about 0.2-0.4 mg/ml 
and used immediately. Protein content of the membranes was determined by the use of dye-
protein binding reaction (18). 
Frog brain membrane preparation: Frog (Rana esculenta) brain membranes were prepared as 
previously described (19). Briefly, whole brains were homogenized in 10 volumes of ice-cold 50 
mM Tris-HCl (pH 7.4) buffer containing 1 mM EDTA, 0.1 mM PMSF, 10 mg/ml bacitracin, and 
40 klU aprotinin (buffer A). The homogenate was centrifiiged at 25,000 x g for 20 min at 4°C. 
The resulting pellet was suspended in the same buffer containing 0.32 M sucrose and stored at -
70°C. Before use, the membrane fraction was thawed, diluted with buffer A and centrifiiged at 
25,000 x g for 20 min at 4°C to remove sucrose. Final pellets were resuspended in buffer A and 
used immediately for ligand binding assays and for G-protein stimulation. 
Radioligand binding studies: [JH]MERF binding assays were performed as described earlier 
(11, 12). Incubations were conducted in 50 mM Tris-HCl buffer (pH 7.4) supplemented with the 
following peptidase and proteinase inhibitors: 1 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA, 1 
mM PMSF, 10 pg/ml bacitracin, 40 KlU/ml trasylol, 1 mM o-phenanthroline, 4 pg/ml soybean 
trypsin inhibitor, 1 mM benzamidine, 4 pg/ml leupeptine, 30 pM bestatin, 30 pM captopril, 0.3 
pM thioiphan, 500 pM Leu-Arg. The final volume was 1 ml that contained 0.2-0.4 mg protein. 
Incubations (0°C, 40 min) were terminated by rapid filtration under vacuum followed by washing 
with 3 x 6 ml ice-cold Tris-HCl (50 mM, pH 7.4) buffer through Whatman GF/C glass fiber 
filters using a Brandel M24R cell harvester. Non-specific binding was defined as the bound 
radioactivity in the presence of 10 pM unlabelled MERF. [JH]naloxone binding assays were 
carried out in a similar way, except that incubation was conducted at 0°C for 60 min, and 
Whatman GF/B filters were used for the separation. Non-specific samples contained 10 pM 
unlabelled naloxone. The radioactivity was measured in a toluene-based scintillation cocktail by 
Wallac 1409 spectrophotometer. All assays were performed in duplicate and repeated several 
times. Equilibrium competition data were analyzed by the use of GraFit computer program 
utilizing the 'four parameter logistic' fitting option for sigmoid displacement curves (20). Data 
are generally expressed as arithmetic means ± standard error of at least 3 repeated assays. 
[35S]GTPyS binding assay: Frog or rat brain membrane fractions (»10 pg of protein) were 
incubated in Tris-EGTA buffer (pH 7.4) composed of 50 mM Tris-HCl, 1 mM EGTA, 3 mM 
MgCl2, containing [35S]GTPyS (0.05 nM) and increasing concentrations (10'9-105 M) of MERF, 
Tyr-D-v4/a-Gly-Phe-Met-Arg-Phe (I) and Tyr-D-^/n-Gly-Phe-D-JV/e-Arg-Phe (II) in the presence 
of 100 pM GDP in a total volume of 1 ml for 60 min at 30°C according to Sim et al., (21) and 
Traynor et al., (22) with slight modifications. Non-specific binding was determined with 10 pM 
GTPyS and subtracted. Bound and free [35S]GTPyS were separated by vacuum filtration through 
Whatman GF/F filters with a Millipore manifold. Filters were washed with 3 x 5 ml ice-cold buffer, 
and radioactivity of the dried filters was detected in a toluene-based scintillation cocktail in a Wallac 
1409 scintillation counter (Turku, Finland). 
Results and Discussion 
The potency of MERF (Tyr-Gly-Gly-Phe-Met-Arg-Phe) and four of its analogs was compared in 
ligand binding experiments using [3H]MERF and the universal opioid antagonist ligand, 
[3H]naloxone in frog and rat brain membranes. These tissues have been reported to carry distinct 
proportions of the opioid receptor types with notably marked differences in their K-binding profile 
(8, 23). Synthetic MERF derivatives inhibited the equilibrium binding of [3H]MERF with 
relatively high affinity in frog and rat brain membrane fractions (Fig. 1, TABLE I). The rank 
order of the potency obtained in homologous and heterologous displacement experiments was 
similar in both tissues: MERF > Tyr-ZM/a-Gly-Phe-Met-Arg-Phe (I) » Tyr-D-zl/a-Gly-Phe-L-
Me-Arg-Phe (III) « Tyr-Gly-Gly-Phe-I-Me-Arg-Phe (IV) » Tyr-D-zt/a-Gly-Phe-D-Me-Arg-
Phe (II). It is suggested that replacement of Met5 with D-Nle5 markedly decreases the affinity of 
derivative (II). 
TABLE I. 
Inhibition of [5H]Met5-enkephalin-Arg6-Phe7 binding to frog brain 
membranes by synthetic peptides with related structure 
Unlabelled peptide ICj0 (nM) 
Tyr- Gly -Gly-Phe- Met -Arg-Phe (MERF) 12.6 ± 4.9 
Tyr -D-Ala-Gly-Phe- Met -Arg-Phe (I) 28 ± 8 
T y r - D - A l a - G l y - P h e - D - N l e - A r g - P h e (II) 640 ± 42 
T y r - D - A l a - G l y - P h e - L - N l e - A r g - P h e (III) 32 ± 9 
Tyr- Gly- Gly-Phe - L - N l e-Arg-Phe (IV) 28 
Frog brain membranes were incubated with 1 nM radioligand in the presence 
of various concentrations of peptides for 40 min at 0°C. Displacement curves 
were then analyzed by non-linear regression algorithm (program GraFit. 
sigmoid fitting, four parameter logistic option). Values represent the mean (± 
S.E.M.) of several independent determinations. 
Binding experiments with [JH]naloxone were performed in the absence and presence of sodium 
ions in rat brain membranes. The effect of 100 mM NaCl is characterized by a decrease in the 
binding affinity. Significant increases of the ICjo values in the presence of sodium ions suggested 
the agonist character of ail the peptides tested (TABLE II). 
Cloned K-, 8- and p-receptors interact with multiple G-proteins (24-26). There are several reports 
in the literature of functionally G-protein coupled p- and 5-opioid receptors in mammalian brain 
membranes (27, 28). However, little data are available on the signaling pathways, including the 
features of G-protein activation, of endogenously expressed K-opioid receptors, especially in frog 
brain membranes. Recently, we described the G-protein types and their activation by K-opioid 
ligands in frog brain membranes (15). Nonhydrolyzable GTP analogues such as 5'-guanylyl-
imidodiphosphate (GppNHp) affect the affinity state of the receptor to agonists due to changes in 
the kinetics of G-protein coupling (29). The specific [3H]MERF binding was inhibited in the 
presence of 100 pM GppNHp in both tissues by slightly decreasing the affinity (Fig 2), suggesting 
that these receptors might be working through heterotrimeric G-proteins. 
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Fig. 1. 
Inhibition of [3H]MERF binding to frog brain membrane preparations by 
various MERF-related peptides. 
Membrane samples were incubated in the presence of 0.8 nM radioligand 
and the stated concentrations of unlabelled peptides for 40 min at 0°C. Each 
point represents the mean of duplicate values in a single experiment that was 
repeated several times. 
In order to confirm this finding the G-protein activation of MERF derived peptides was examined 
with the ligand stimulated [J~S]GTPyS binding assay which reflects the GDP-GTP exchange 
reaction on a-subunits of G-proteins by receptor agonists. Detectable stimulation of [J~S]GTPyS 
binding could only be measured in the absence of protease inhibitors which were usually present 
in the binding experiments (12). Integrity of the peptides was therefore checked by HPLC after 
the incubation with brain membranes as written in ref. 12. No significant degradation of the 
peptides was detected at the end of 60 min incubation at 30°C with either tissue preparations 
under the conditions of [ J 'S]GTPyS binding measurements. Tipically, peptides displayed more 
than 98% recovery in the chromatographic run, so their stability was satisfying. 
TABLE II. 
Inhibition of [3H]Met5-enkephalin-Arg6-Phe7 or [3H]naloxone 
binding to rat brain membranes by synthetic peptides with related structure 
Unlabelled peptide IC50 (nM) 
[3H]MERF [3H]naloxone 
-Na + +Na+ 
Tyr- Gly -Gly-Phe- Met -Arg-Phe (MERF) 9.9 ± 1.3 32 116 
Tyr-D-Ala-Gly-Phe- Met -Arg-Phe (I) 33 ± 17 29 147 
Tyr -D-Ala-Gly-Phe -D-Nle-Arg-Phe (II) 307 ± 3 8 112 845 
Tyr -D-Ala-Gly-Phe -L-Nle -Arg-Phe (III) 23 ± 8 36 494 
Tyr- Gly- Gly-Phe-L-Nle-Arg-Phe (IV) 25 ± 18 11 220 
Rat brain membranes were incubated in the presence of various concentrations of 
peptides with each of the radioligands and then filtered. Incubation conditions were: 
40 min, 0°C for [3H]MERf ; 60 min, 0°C for [3H]naloxone. Displacement curves 
were analyzed by non-linear regression algorithm (program GraFit, sigmoid fitting, 
four parameter logistic option). Values represent the mean (± S.E.M.) of several 
independent determinations. 
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Fig. 2. 
Effect of sodium ions and GppNHp on [ JH]MERF equilibrium binding in frog (left) 
and rat (right) brain membranes. 
Homologous displacement experiments were carried out in the absence and presence 
of regulators. O: binding in the absence of exogenous regulators; • : 100 mM 
NaCl; • : 100 pM GppNHp; • : combination of 100 mM NaCl and 100 pM 
GppNHp. Duplicate data of single experiments were analyzed by the GraFit 
program. Kj values were as follows: Frog: 1.8 nM in buffer, 3.9 nM, in the 
presence of 100 pM GppNHp; Rat: 6.2 nM in buffer alone, 10.8 nM in the 
presence of 100 pM GppNHp. 
The effect of the peptides was examined using increasing concentrations (10"9-10°) of MERF and 
its derivatives. All of the peptides investigated resulted in a concentration-dependent stimulation 
of [35S]GTPyS binding, which implied that these receptors functionally couple to G-proteins (Fig. 
3). Our experiments were performed at high GDP concentration, which was required to 
demonstrate differences in the relative efficacies (30). Analog (II) was found to be the least 
efficacious ligand for stimulation of [33S]GTPyS binding in both tissues (TABLE III). Analog (I) 
displayed similar maximal stimulation to MERF in rat but lower than MERF in frog brain 
membranes which might be due to differences in the receptor specificity of the two peptides 
(TABLE HI, Fig. 3). The EC50 values of analog (II) were the highest in both tissues which refer to 
the lowest potency of this peptide (TABLE III). These results are in a good agreement with those 
obtained in the ligand binding experiments. We concluded, that substitution of Met3 by D-Nle3 
leads to a decrease of the potency of this peptide. 
TABLE HI. 
Potency (EC50) and maximal effects of MERF and its derivatives in stimulating 
[35S]GTPyS binding in frog and rat brain membranes. 
Peptide ECJO (nM) Maximal stimulation (%) 
frog Rat frog rat 
MERF 6.7±12 21 ±10 116+1.4 99 ±5.8 
Tyr-D-ALa-Gly-Phe-ifet-Arg-Erifi (I) 9.8 ±4 24 ±16 81.6 ±02 105 ±2.1 
Tyr-rhAIa-Gly-Fhe-I>WLe-Arg-Erie (H) >1000 160± 14 — 59±6 
Agonist stimulated [33S]GTPyS binding was determined as described in Materials and 
Methods. The parameters shown were obtained from nonlinear regression analysis using the 
program Graph Pad Prism 2.01 and considering a sigmoidal dose response curve. Data are 
mean ± S.E.M. of 3 experiments each performed in triplicate. EC50 values were defined 
as the concentration of the ligand producing 50 % of the maximal response. Maximal 
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Basal activities measured in the absence of opioid ligands were 70.6 i 6 fmol/mg protein 
and 26 ± 2 fmol/mg protein in frog and rat brain membranes, respectively. 
Previously it has been shown that MERF binds to K2- and 5-opioid binding sites, as well as to 
non-opioid sites, but no binding to K|- or p-opioid receptors could be established in rat and frog 
brain membranes (11, 12). The receptor specificity of the peptides was further investigated by 
measuring the inhibition of agonist stimulated [j3S]GTPyS binding by p-, 5- and K-selective 
opioid antagonists. Norbinaltorphimine (nor-BNI), a K-receptor selective antagonist displayed 
high potency in inhibiting the effects of MERF or its analog. Nevertheless, the 5-opioid 
antagonist naltrindole was also very potent in both tissues. The p-selective antagonist cyprodime 
was the least effective (Fig. 4, TABLE IV). Thus it can be deduced that the effects of MERF and 
analog (I) are mediated the least by p-opioid receptors. These results agree with the receptor 
binding experiments using [3H]DAMGO (data not shown). 
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Fig. 3. 
Effect of MERE and its derivatives on [ j5S]GTPyS binding in frog (A) and rat (B) brain 
membranes. Membranes («10 pg of protein) were incubated in Tris-EGTA buffer (pH 7.4) 
composed of 50 mM Tris-HCl, 1 mM EGTA and 3 mM MgCB, containing [35S]GTPyS (0.05 nM) 
in the absence (basal activity), or in the presence of various concentrations of MERF ( • ) , Tyr-D-
H/a-Gly-Phe-Met-Arg-Phe (I) (A), Tyr-D-H/a-Gly-Phe-D-Me-Arg-Phe (II) ( • ) in the presence of 
100 pM GDP in a total volume of 1 ml for 60 min at 30°C as described in materials and methods. 
Data are mean ± S.E.M. of three experiments each performed in triplicate. Data were fitted with 
Graph Pad Prism 2.01. 
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Fig. 4. 
Inhibition of ligand (MERF and Tyr-ZMfra-Gly-Phe-Met-Arg-Phe (I) in frog and rat brain 
membranes, respectively) stimulated [ j3S]GTPyS binding by antagonists in frog (A) and rat (B) 
brain membranes. Membranes (« 10 pg of protein) were incubated in Tris-EGTA buffer (pH 7.4) 
composed of 50 mM Tris-HCl, 1 mM EGTA and 3 mM MgCl2, containing [35S]GTPyS (0.05 nM) 
and 100 pM GDP in the absence (basal activity), or in the presence of 1 pM MERF in frog and 1 
pM Tyr-Z)-/l/a-Gly-Phe-Met-Arg-Phe (I) in rat with increasing concentrations of nor-BNI ( • ) , 
naltrindole (A) and cyprodime ( • ) . Incubation and filtration were performed as described in 
materials and methods. Data are mean ± S.E.M. of three experiments each performed in triplicate. 
Data were fitted with Graph Pad Prism 2.01. 
TABLE IV. 
Effect of opioid receptor antagonists on agonists stimulated 
[35S]GTPyS binding in frog and rat brain membranes. 
Selective antagonists IC50 GiM) 
Frog brain Rat brain 
Norbinaltorphimine (K) 0.67 ±0.01 4.0 ± 0.09 
Naltrindoie (8) 0.56 ±0.01 4.1 ±0.32 
Cyprodime (p) 0.85 ± 0.02 4.6 ±0.15 
Frog or rat brain membrane fractions (»10 pg of protein) were incubated in 
Tris-EGTA (50 mM Tris-HCl pH 7.4, 1 mM EGTA and 3 mM MgCl2) buffer 
containing [35S]GTPyS (0.05 nM) and 100 pM GDP in the absence (basal 
activity), or in the presence of 1 pM MERF in frog and 1 pM Tyr-D-Ala-
Gly-Phe-Met-Arg-Phe (I) in rat with increasing concentrations of Nor-BNI, 
naltrindoie and cyprodime. The parameters shown were obtained from 
nonlinear regression analysis using the program Graph Pad Prism 2.01 and 
considering a model of one site competition curve. IC50 values were defined 
as the concentration of the antagonist producing the 50 % of the maximal 
effect. Data are mean ± S.E.M. of 3 experiments each performed in 
triplicate. 
The IC50 values of the antagonists in inhibiting G-protein stimulation were significantly lower in 
frog than in rat brain membranes (TABLE IV). This agrees with our previous ligand binding data 
obtained in the two preparations (11, 12). Opioid antagonists seemed to be more effective in 
inhibiting the effects of the agonists in frog brain membranes referring to their higher affinity to 
these binding sites. I t /»tl^l.t L.^  ^ ^ w . c d by the different properties of the receptors displayed in 
the two tissues. Indeed, ligand affinités, stereoselectivity and the proportions of opioid receptor 
types have been reported to be characteristically different in amphibian brain (8, 13, 19), 
permitting us to designate the major type of opioid receptors in frog as ic2-receptor (10). Other 
investigators termed this particular receptor-type either as 'op'-receptor (31), or more recently the 
'unireceptor' term has been introduced (32). Apart from its name, this opioid receptor type in frog 
brain possesses similarly high affinities to non-selective antagonists e.g., naloxone, naltrexone 
and diprenorphine as well as to the K-selective norBNI and 6-selective naltrindoie. These 
findings are in good agreement with the equivocally high potencies of the antagonists observed in 
frog brain GTPyS binding assays. 
Summarizing our results, the natural opioid peptide Met3-enkephalin-Arg6-Phe7 (MERF) and its 
synthetic derivatives are high affinity ligands in [JH]MERF and [JH]naloxone binding assays with 
the exception of analog (II). MERF-related peptides are able to activate G-proteins via opioid 
receptors, but they have no distinctive selectivity to any of the opioid receptor types in frog and 
rat brain crude membrane fractions, at least under the conditions of [J5S]GTPyS binding 
measurements. The enzymatic stability of the synthetic D-Ala and D-Nle containing MERF-
derivatives is quite good because no decomposition was observed in the presence of the 
membrane preparations. Some of these peptides are selected for radiolabelling and will be used 
in experiments investigating multiple MERF binding sites in the central nervous systgnf 
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Abstract 
This paper describes Western-blott ing evidence for the presence of various guanine nucleotide binding proteins, G-prote ins in 
cultured rat cerebral endothelial cells (CECs) and two immortalized cerebral endothelial cell lines, RBE4 and GP8 By using specific 
antibodies raised against known sequences of appropr ia te G-pro te in types that were previously characterized, we demonstra ted the 
presence of G,x, G l 2a. G,3a, G q n a , G„a and G/J in cell lysates of pr imary cultures of CECs , and plasmamembranes of RBE4 and 
G P 8 cells. T h e appearance of G„2 proteins in C E C s might be of special impor tance , since they were not detected in peripheral 
endothelial cells in previous studies. Isoproterenol and bradykinin displayed significant, dose-dependent stimulation of [3 iS]GTPyS 
binding above basal values. This assay, reflecting the G D P - G T P exchange reaction on Ga-subuni t s by receptor agonists, suggested 
that there were functional , G-prote in coupled ^-adrenergic and bradykinin receptors in these systems. No significant st imulation of 
[35S]GTPyS binding was noted with serotonin under our experimental condit ions. Since stimulation of [ !5S]GTPyS binding by 
isoproterenol and bradykinin was additive, it was concluded that different Got proteins were activated by these two ligands. In 
analogy to o ther systems, activation of G , is most likely by isoproterenol, while G> and /o r Gq/11 proteins might be activated by 
bradykinin receptors. The possible significance of the receptors and G-prote ins detected is being discussed in the functioning of 
cerebral endothel ium, and thus the blood-brain barrier. © 1998 Elsevier Science Ltd. All right- reserved 
Key wards Cerebral endothelial cells: G-proteins: Brads kinin; //-adrenergic receptors: ("SJGTPyS binding 
1. Introduction 
By forming the morphological substrate of the blood-
brain barrier (BBB), cerebral endothelial cells (CECs) 
play a crucial role in transporting various substances 
between the blood and brain, and in maintaining the 
homeostasis of the central nervous system (CNS). In 
order to accomplish this complex task, CECs should be 
equipped with specific receptors and proper signal trans-
duction pathways. Among others, //-adrenergic ( D u n e u -
Trautmann et al., 1991), bradykinin (Homayoun and 
• Corresponding author. Tel.: 0036 62 432 232: fax: 00 36 62 433 506: 
e-mail: szucsm(a everx szbk u-szeged.hu 
+ Deceased. 
Abbreviations—BBB. blood-brain barrier: CECs. cerebral endo-
thelial cells; CNS. central nervous system; PLC. phospholtpase C; 7TM 
receptors. 7 transmembrane domain containing receptors: G-protein. 
heterotrimeric guanine nucleotide binding regulatory protein; GTPyS. 
guanosine-5'-0-(3-thio)triphosphate: GDP. guanosine 5'-diphosphate; 
SDS-PAGE. sodium dodecyl sulfate Polyacrylamid gelelectrophoresis. 
Harik, 1991; Revest et-al., 1991). histamine type H, and 
H, (Karnushina et al.. 1980; Spatz et al., 1989), P, purino 
(Revest etal . , 1991; Nobles et al., 1995), dopamine (Bacic 
et al., 1991), endothelin (Vigne et al., 1990; Stanimirovic 
et al., 1994), V, vasopressin (Hess et al., 1991). atrial 
natriuretic peptide (Smith et al.. 1988) receptors have 
been demonstrated in brain endothelium 
In recent years considerable progress has also been 
made in the identification of the effector molecules that 
are present in CECs including adenylvl cyclase (Joo et 
al., 1975), protein kinase C (PKC) family members 
(Krizbai et al., 1995), calcium/calmodulin-stimulated 
protein kinase II (CaM-PK II) (Deli et al.. 1993). nitric 
oxide synthase (NOS) (Durieu-Trautmann et al.. 1993), 
phospholipase A2 (Paglan et al., 1993). However, little is 
known about the pathways leading to the activation of 
these effectors. One group of the membrane receptors 
exerts its intracellular effects via coupling to hetero-
trimeric G-proteins that, when activated, will act to 
modulate different intracellular signalling molecules and 
0197-0186/98 S19.00 © 1998 Elsevier Science Lid. All rights reserved 
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enzymes (Offermanns and Schultz, 1994; Gudermann et 
al., 1996). G-proteins form a permanently growing family 
of proteins composed of three subunits, a, /? and y of 
which at least 23 a, 6 different ft and 11 y isoforms are 
known to date (for recent reviews see Helmreich and 
Hofmann, 1996;Kalkbrenneret al., 1996). The a subunits 
can be further classified into subfamilies of which the G s 
and G¡ types regulate, above all but not exclusively, the 
enzyme adenylyl cyclase. G ^ , types in most cases are 
linked to phospholipase C (PLC), whereas G 0 types are 
believed to couple to ion channels. 
Owing to their strategic role in signal transduction, the 
expression and role of different G-proteins have been 
investigated in various types of endothelial cells in a large 
number of studies (Gil-Longo et al., 1993; Day et al., 
1995; Liao and Homey, 1993a and 1993b). It has been 
shown for example that bovine aortic endothelial cells 
express a complex set of G-proteins such as Guoc, Gi2a, 
G i3a, G^u«. G,a, but no G„a (Gil-Longo et al., 1993). 
The aim of our work was to describe the presence of 
various types of G-proteins in CECs, a highly specialized 
endothelium, and to find possible ways of their activation 
by diverse receptor agonists. 
2. Experimental procedures 
2.1. Primary cultures of rat CECs 
Cultures were prepared as described in details earlier 
(Deli et al., 1997), from 2-week-old rat brains. All CFY 
rats used for the primary cultures of CECs were acquired 
from the local animal house and were cared for in accord-
ance with NIH guidelines. Animal experiments were 
approved by the ethical committee of the Biological 
Research Center, Szeged. Cultures were maintained in 
Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 20% plasma derived bovine serum (PDS), 
2.0 mM glutamine and antibiotics at 37°C in a humidified 
atmosphere of 5% C0 2 and 95% air. To further purify 
cultures of CECs, a selective cytolysis of contaminating 
cells by specific anti-Thy 1.1 antibody and complement 
was performed (Risau et al., 1990). After 7 days in vitro, 
endothelial cells developed continuous monolayers which 
were used for the experiments. The cultures were regu-
larly tested for Factor VIH-related antigen, and over 98% 
of the cells expressed positivity. 
2.2. Endothelial cell lines 
GP8 cells (Greenwood et al., 1996) were cultured in 
DMEM supplemented with 20% PDS, 1 ng/ml basic 
fibroblast growth factor (bFGF) and 300 jig/ml G418 
and used between passages 15-20. RBE4 cells (Roux et 
al., 1994) were cultured in DMEM plus 10% fetal calf 
serum, 1 ng/ml bFGF and 300 pg/ml G418 and used 
between passages 32-47. Both cell lines expressed general 
endothelial as well as specific cerebral endothelial features 
as published (Greenwood et al., 1996; Roux et al., 1994). 
2.3. Cell membrane preparation 
Cell cultures were washed twice with phosphate buffered 
saline (PBS); the monolayers were detached from the 
plastic by tissue scraper and suspended in PBS (pH 7.4). 
Samples were sedimented for 10 min at 3000 x g (4°C) 
and the pellets were then suspended in 10 ml lysis buffer 
(5 mM Tris-HCl, 50 pM CaCl2, 0.5 mM dithiothreitol, 
and 0.1 mM phenylmethyl-sulfonyl fluoride, pH 8.1) fol-
lowed by homogenization in a glass teflon potter at 4°C. 
The homogenate was centrifuged for 5 min at 3000 x g 
and the resulting supernatant spun at 20,000 x g for 30 
min. Membrane pellets obtained were suspended in 50 
mM Tris-HCl (pH 7.4) to yield about 0.4-1 mg 
protein/ml, and either freshly used for [MS]GTPyS studies 
or kept frozen at — 70°C until used for immunoblotting. 
Protein content was determined with bovine serum albu-
min as a standard according to Bradford (Bradford, 
1976). 
2.4. Gel electrophoresis and immunoblotting 
SDS-PAGE was performed according to Laemmli 
(Laemmli, 1970) with modifications. Membrane samples 
of RBE4 and GP8 cells were delipidated in meth-
ano!:chloroform:water mixture (4:1:3), spun down in an 
Eppendorf centrifuge, washed with methanol and the 
pellet resuspended in sample buffer. Cells from the pri-
mary culture were lysed m sample Duner. sonicated for 1 
min and boiled for 5 min. Equivalent amounts of proteins 
(30-80 /ig) were loaded onto a 16 cm long 10% slab 
gel containing high purity, deionized urea (6 M), which 
improved the resolution of Ga and G/J subunits with 
molecular weights close to each other (Ribeiro-Neto and 
Rodbell, 1989; Hinsch et al., 1989). Electrophoresis was 
performed at room temperature at a constant voltage of 
150 V for 6 h. Proteins resolved by SDS-PAGE were 
transferred onto nitrocellulose membranes at a constant 
current of 200 mA for 1 h in a three buffer component 
semi-dry system (Kyhse-Andersen, 1984). Transfer buffer 
1 contained 0.3 M TRIS-HC1, 20% methanol; transfer 
buffer 2 and 3 consisted of 25 mM TRIS-HC1, 20% 
methanol; and 25 mM TRIS-HC1, 20% methanol, 40 
mM c-amino-caproic acid, respectively. Nitrocellulose 
membranes were stained with amido-black for evaluation 
of the protein loading and transfer, blocked for 1 h in 
3% ovalbumin in TRIS-buffered saline (TBS), pH 7.4. 
Thereafter, filters were cut into stripes and incubated 
for 1 h with various anti-G-protein antisera which were 
diluted in TBS (pH 7.4) supplemented with 1 % (w/v) BSA 
(fr. V., protease free) and sodium azide. After washing 4 
times with TBS supplemented with 0.05% (v/v) Tween-
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20 (TBS/Tween) for 15 min filters were blocked again 
as above and subsequently incubated with the second 
antibody (goat anti-rabbit IgG, peroxidase conjugated, 
diluted 1:1000) in TBS/BSA for 1 h. The extensive wash-
ing was repeated and labelled protein bands were vis-
ualized by ECL reagent on Kodak X-OMAT AR film. 
Films were analyzed by an LKB Ultroscan XL Enhanced 
Laser Densitometer and GelScan XL Laser Densitometer 
Program computer software. 
2.5. [25S\GTPyS binding assay 
Endothelial cell membranes (Ä:10 gg of protein) were 
incubated in Tris-EGTA (50 mM TRIS, 1 mM EGTA, 3 
mM MgCl2 pH 7.4) buffer containing [35S]GTPyS (0.05 
nM) and increasing concentrations (10-8—10-4 M) of sti-
mulating ligands in the presence of 100 gM G D P in a 
total volume of 1 ml for 60 min at 30°C, according to 
Sim et al., 1995 and Traynor and Nahorski, 1995. Iso-
proterenol was dissolved and diluted in 10 mM TRIS-
HC1, pH 7.4 containing 1.1 mM ascorbic acid. Non-
specific binding was determined with 10 jtM G T P / S and 
subtracted. Bound and free [35S]GTPyS were separated 
by vacuum filtration through Whatman GF/B filters with 
a Millipore manifold. Filters were washed with 3 x 5 ml 
ice-cold buffer, and radioactivity was detected after dry-
ing in a toluene based scintillation cocktail in a Searle 
liquid scintillation counter. 
2.6. Materials 
Urea was purchased from Merck, ion-exchange resin for 
I.-IVJ-JVI AJf AUS llvlltl L>iv-l\,tu. LOU AlUlvuUlUl 
Weight markers were from Pharmacia, nitrocellulose 
(Hybond) and ECL were from Amersham. Anti-G-pro-
tein antibodies As/7 (anti-G ; i 2a; 1:500), RM/1 (anti-G,a; 
1:500) and GC/2 (anti-G0a; 1:500) were from Du Pont-
N E N . AS 11 (anti-G/I-common; 1:300) (Hinsch et al., 
1989), AS 369 (ant i -G^.a ; 1:1000) (Offermanns et al., 
1994), AS 269 (anti-G,2a; 1:150) (Laugwitz et al., 1993) 
and AS 86 (preferentially anti-G i3a; 1:500) (Nürnberg et 
al., 1994) were characterized and kindly donated by Prof. 
G. Schultz and Dr K. Spicher (Freie Universität Berlin, 
Germany). [35S]GTPyS (37-42 TBq/mmol) was obtained 
from IZINTA (Budapest, Hungary). All other chemicals 
were purchased from Sigma. 
3. Results 
3.1. Western-blots 
G-protein composition of primary cultures of rat brain 
endothelial cell lysates and that of plasma membranes of 
immortalized rat brain endothelial cell lines, RBE4 and 
GP8, was studied with immunoblotting using specific 
antisera against different G-protein subtypes. SDS-
PAGE separation of proteins was performed in the pres-
ence of urea to improve resolution of the Ga subunits of 
closely similar molecular weights (39-43 kDa) (Ribeiro-
Neto and Rodbell, 1989; Hinsch et al., 1989). Basically, 
all the Ga subunits tested were present in the three types 
of CECs studies with only slight quantitative differences 
(Fig. 1). Antiserum AS 369 (anti-G^na) detected a pro-
tein band which, however, was in many experiments 
resolved into two distinct bands. Even in cases where the 
resolution was not so clear, the densitometric analysis of 
the films revealed the presence of two peaks very close 
to each other. With antiserum RM/1 (anti-Gsa) heavy 
A ^ ^ CM O 
o- ( f ) o £ ™ !2 
Fig. 1. Immunoblot analysis of G-prolein i subunits in primary cultured 
rat brain endothelial cell lysates (A), or crude membranes of RBE4 (B) 
and GP8 (C) cell lines. Samples were run on SDS-PAGE containing 
urea and transferred onto nitrocellulose membranes. Immunoblotting 
was performed with specific anti-peptide antisera which recognise G-
proteln z subunits indicated on the top of each lane. Filter-bound 
antibodies were detected by ECL system. Molecular weights in kDa are 
indicated on the right. 
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staining of proteins of 43 kDa was seen. A minor band 
of about 42 kDa was also detected mainly in GP8 cell 
membranes (Fig. 1, panel C). This latter protein was 
sometimes also seen in the other two CECs tested. Anti-
serum GC/2 (anti-G0a) detected a faint band at approxi-
mately 41 kDa, and a more intense staining at about 39 
kDa. Antiserum AS/7 (anti-Gi,ot and G^cc) recognised 
one bulky band which comigrated with the G i2a labelled 
band obtained by incubation of the membranes with AS 
269 (anti-Gl2cc). In RBE4 and GP8 cell membranes a faint 
band of approx. 42 kDa was also detected with AS7 (Fig. 
1, B and C) which was not seen in lysates of primary cell 
cultures (Fig. 1, A) and might be G u a . AS 86 (pref-
erentially anti-G i3a) detected 2 bands of which the upper 
band might be G i3a and the lower one G 0 a based on the 
known cross-reactivity of AS 86 with G 0a (Simonds et 
al., 1989; Nürnberget al., 1994), and also thecomigration 
of this band with the lower band of the GC/2 (anti-G0a) 
detected bands (Fig. 1). 
The G/?-specific antiserum AS 11 detected a doublet 
with molecular weights of 40 and 41 kDa in the tissues 
tested (data not shown) that are somewhat higher than 
the values obtained in most tissues, i.e. 35 resp. 36 kDa 
(Hinsch et al., 1989), and might be due to the presence of 
urea in the gel. 
3.2. [}5S]GTPyS binding 
In order to see which receptors might be functionally 
coupled to the G-proteins in rat brain endothelial cell 
lines, ligand stimulated [35S]GTPyS binding was mea-
sured in plasmamembranes of RBE4 and GP8 cells (Fig. 
2). The low yield of the primary CECs cultures, giving 
about 1 mg protein of cell homogenate from cultures 
started from ten rat brains (Deli et al., 1997), which yield 
was further reduced to approximately 100 /ig of total 
protein during membrane preparation prompted us to 
use only the immortalized cell lines in the [35S]GTPyS 
binding studies. It has been shown in previous studies 
that G D P is necessary to observe significant stimulation 
of [35S]GTPyS binding by most agonist ligands (Sim et 
al., 1995). Thus, our assays were performed with G D P in 
p M concentrations. Basal activities were similar in both 
cell lines (RBE4: 22 ± 1.7 fmol/mg protein; GPS: 20 ± 1.9 
fmol/mg protein, mean ±S.E.M ). Highest stimulation 
was achieved with the //-adrenergic receptor agonist iso-
proterenol in both endothelial cells (Fig. 2). Bradykinin, 
a bradykinin receptor agonist stimulated [35S]GTPyS 
binding to about the same degree («20 -30%) in both 
cell lines. No significant stimulation of [35S]GTPyS bind-
ing was noted using serotonin. To exclude the possibility 
that the absence of serotonin stimulation might be due 
to a different basal activity of the serotonin-coupled G-
proteins, the concentration of G D P was varied between 
1-100 /zM and the effect of serotonin was evaluated (data 
not shown). The results confirmed our previous obser-
vations, namely that highest stimulation can be achieved 
at 30-100 jrM G D P which however was not statistically 
different f rom the values obtained in the absence of sero-
tonin. 
In the next experiment the additivity of the effect of 
isoproterenol and bradykinin was tested in GPS cells 
(Fig. 3). It was speculated that if different Got proteins 
are activated by these receptor agonists (as expected), 
then the resulting [35S]GTPyS binding should be the sum 
of those measured in the presence of each ligand alone. 
This was exactly the case, 10~5 M isoproterenol alone 
elevated the enzvme activity above basal values by 80% 
- 7 - 6 -5 - 4 
log[ l igand].M 
B 
150 
-5 
log[l igand],M 
Fig. 2. Ligand stimulated [3iS]GTPyS binding in crude membranes of RBE4 (A) and GP8 (B) cell lines Proteins 10 pg) were incubated with 
[ SJGTP-/S (0.05 nM) and various concentrations ( 1 0 " > - I 0 - ' M) of isoproterenol ( • ) . serotonin ( • ) . or bradykinin (A) in the presence of 100 /iM 
G D P for 60 mm at 30°C. Nonspecific binding was determined with 10 /iM GTPyS and subtracted Basal activity i e binding in the absence of 
stimulating ligands was 22.9± 1.7 and 20.0± 1.9 f m o l x m g protein" ' in RBE4 and GPS membranes, respectively Points are means±S.E .M. from 
3-7 independent experiments, each performed in triplicate. Where error bars are not shown, the SEM was smaller than indicated bv the symbol. 
< 0.05. 
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Fig. 3. Additivity of the effect of isoproterenol and bradykinin on 
("SJGTPyS binding in GP8 cell membranes. Isoproterenol in 10~s M 
was probed alone (open bar), or in the presence of 10~'-10~* M bra-
dykinin (filled bars). * denotes those points where the latter are sig-
nificantly different from the former, mP < 0.05. Values are 
means+ S.E.M. from 3 independent experiments. 
(Fig. 3, open bar). This value was further increased by 
bradykinin depending on its concentration, highest 
stimulation being seen when 10"4 M bradykinin was also 
present together with 10~5 M isoproterenol (Fig. 3, filled 
bars). 
4. Discussion 
In this work we identify the G-proteins that are present 
in cerebral endothelial cells. Highly purified primary cul-
tures of CECs were studied to avoid possible astrocytic 
and pericytic contamination (Risau etal. , 1990). By using 
specific antibodies raised against various G-protein sub-
types and immunoblot techniques, we were able to dem-
onstrate the presence of a complex set of G-proteins such 
as G sa, G i2a, G l3a, Gq/11a, G„a and G 0 in CECs. The 
same proteins were also present in the two immortalized 
cerebral endothelial cell lines tested, i.e. RBE4 and GP8 
which showed similar morphological and functional 
characteristics to primary CECs (Roux et al., 1994; 
Greenwood et al., 1996). 
The presence of the principal stimulatory G-protein, 
G,x in CECs shown in our study (Fig. 1) may constitute 
an important element in coupling different 7TM receptor 
proteins to intracellular signalling pathways. Previously 
certain 7TM receptors, known to be coupled to G,a in 
other systems, like /(-adrenoceptors (Durieu-Trautmann 
et al., 1991), histamine H-2 receptors (Kamushina et al., 
1980), and dopamine D-l receptors (Bacic et al., 1991) 
have been shown to be expressed by the cerebral endo-
thelium. Activation of these receptors may lead to 
increased intracellular cAMP levels. Increased endo-
thelial cAMP levels in turn have been shown to regulate 
BBB permeability in vivo (Joó et al., 1975) and in vitro 
(Rubin et al., 1991; Deli et al., 1995), and to inhibit 
endothelial cell proliferation (Sexl et al., 1995). 
Inhibitory G-proteins have also been detected on the 
cerebral endothelium (Fig. 1). To our knowledge this is 
the first report describing the presence of G-proteins in 
cells of endothelial origin. This might be characteristic to 
brain endothelial cells since no detectable amount of G0a 
was expressed in peripheral endothelial cells (Gil-Longo 
et al., 1993), and might support the highly specialized 
function of brain endothelial cells, namely, the main-
tenance of BBB. Previous studies have demonstrated the 
expression of different G¡ types (Gi2a and G i3a) in per-
ipheral endothelial cells with the predominance of G i2a, 
and their role in stimulating endothelial cell proliferation 
and angiogenesis (Sexl et al., 1995; Bauer et al., 1992). In 
this respect the CECs have similar characteristics express-
ing significant amounts of G i2a and G j3a (Fig. 1). Acti-
vation of these G-proteins have been shown to decrease 
intracellular cAMP levels and activate K + channels in 
other systems. 
G-proteins possibly coupling membrane receptors to 
phospholipase C (PLC) turned out to be present in CECs 
as well (Fig. 1). Similarly to its demonstrated role in 
peripheral endothelium, G^, ,« may be involved in media-
ting the effect of potent vasoactive substances like bra-
dykinin (Liao and Homey, 1993b), histamine (Mancusi 
et al., 1996), endothelin (Eguchi et al., 1993), thrombin 
(Stasek and Garcia, 1992) and fibrin (Chang et al., 1995). 
Moreover, G-proteins may be involved in the regulation 
of ion channels as well. 
Our results obtained with ligand stimulated 
( "S]GTPyS binding experiments using isoproterenol and 
bradykinin suggested that /(-adrenergic and some brady-
kinin receptors were present in membrane fractions pre-
pared from RBE4 and GP8 cells, and activation of these 
receptors resulted in functional activation of some (but 
unknown) G-proteins (Fig. 2). In agreement with our 
results, functional /(-adrenoceptors have also been 
demonstrated by other techniques in CECs (Durieu-
Trautmann et al., 1991) and also in RBE4 cells (Durieu-
Trautmann et al., 1993). 
Bradykinin, another receptor agonist only weakly 
20-30%), but significantly elevated [35S]GTPyS bind-
ing in both cell lines tested (Fig. 2). High affinity brady-
kinin receptor of B2 type on rat cerebral microvessel 
was described (Homayoun and Harik, 1991). Moreover 
bradykinin increased the intracellular free Ca2 + in cul-
tured rat CECs (Revest et al., 1991). Activation of brady-
kinin receptors may be coupled to the regulation of vas-
cular tone and nitric oxide release via cholera toxin sen-
sitive G-proteins as it has recently been demonstrated 
in peripheral endothelium (Gil-Longo et al., 1993). The 
possible coupling of bradykinin receptors to PLC via 
Gq may lead to activation of phospholipid signalling. 
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Bradykinin enhances the permeability of endothelial 
monolayers in the periphery (DeFouw et al., 1993; Ehr-
inger et al., 1996). It also causes a rapid and irreversible 
decrease in transendothelial electrical resistance in pial 
microvessels of rats acting on the basal membranes (Butt, 
1995). These data strengthen a role for bradykinin in 
brain oedema formation. 
Serotonin augmented the extravasation of macro-
molecules across peripheral venules (Feng et al., 1996), 
while its effect on the permeability of the BBB is con-
troversial. In frog pial venules, enhanced reversible ionic 
permeability was observed after administration of the 
mediator (Olesen and Crone, 1986) while in pial mic-
rovessels of rats no effect was seen (Butt, 1995). The lack 
of stimulation of [3SS]GTPyS binding by serotonin in GP8 
and RBE4 cells (Fig. 3) might be due to the conditions 
used in our experiments, although it was tested at various 
GDP concentration which did not improve the effect 
measured (data not shown). Literature data, namely that 
while bradykinin, ATP and histamine elevated the intra-
cellular free CA2+ in primary cultures of rat CECs, sero-
tonin caused no detectable effect (Revest et al., 1991), 
support our observation. The possibility of altered 
responsiveness to vasoactive mediators in specific seg-
ments of the cardiovascular system (periphery vs BBB, 
large vessels vs capillaries etc.), or species differences 
should also be considered. 
This work was not aiming at identifying the type of Got 
proteins that have been activated by the receptor ligands 
tested in [35S]GTPyS binding experiments. However, from 
the observation that the stimulating effect measured when 
both isoproterenol and bradykinin were present in the 
assay was the sum of activation measured with each 
ligand alone (Fig. 3). it was concluded that different Got 
proteins were activated by these two ligands. In analogy 
to other systems, activation of G, is most likely by iso-
proterenol, while G ; and G^n proteins might be activated 
by bradykinin receptors. The validity of this speculation, 
as well as the pharmacological characterization of these 
receptors will require further investigations. Also, in 
order to demonstrate definitively that these various recep-
tors and Ga proteins are expressed by endothelial cells. 
Northern-blots, in situ hybridization and so on, will be 
required. Nevertheless, to our knowledge this is the first 
study to identify the G-protein types in cerebral endo-
thelial cells, and thus it may prepare the ground for future 
work. 
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